REG - GenIP PLC Tekcapital plc - Trading Statement

TekcapitalAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250725:nRSY4923Sa&default-theme=true

RNS Number : 4923S  GenIP PLC  25 July 2025

 

 

25 July 2025

 

GenIP Plc

("GenIP" or the "Company")

 

H1 2025 Trading Statement

 

Growing Order Book and Cash Balance

 

GenIP Plc, a technology business providing Generative Artificial Intelligence
(GenAI) services to help research organisations and corporations commercialise
their innovations, is pleased to issue the following trading statement for H1
2025.

 

GenIP continues to build momentum. The Company's cash balance increased to
$1,077k at 30 June 2025 (31 December 2024: $972k) driven by record orders and
effective cost controls. In the first half of 2025, we secured $488k in new
orders, including material contract wins in Asia, expanding our catchment
market, which have positively impacted working capital.

Total orders received since GenIP's AIM listing in October 2024 stand at
$981k, and the outstanding order book totals $813k, providing visibility of
revenue generation in H2 2025.

The business was acquired by GenIP in June 2024 and the strategic ramp-up of
expenditure and marketing took place following the October 2024 IPO, so there
is no direct comparability between H1 2025 and FY2024 revenue performance.

Nevertheless, H1 2025 revenue is expected to reach approximately $128k,
modestly ahead of PE2024's total ($123k). This uplift reflects the timing of
several significant orders secured in the first half, which are scheduled for
delivery and revenue recognition in H2. These early wins underscore the
commercial progress made since IPO and position the Company for continued
growth in the second half of the year.

The Company continues to maintain a strong pipeline of new business as it
delivers on its global growth strategy. During the period, GenIP has entered
new markets including Brazil, Chile and the UK academic market. In addition to
the continued growth of existing products, the Company looks forward to
enhancing revenue generation by launching new products currently in
development phases. GenIP's Invention Evaluator services accounted for the
majority of first half revenue and orders, with Vortechs expected to make a
more significant contribution in the second half.

Investment in technology development continues with delivery expected at the
beginning of Q3, serving as a growth enabler.

 

Outlook

 

GenIP is in a robust position with clear revenue visibility going into the
second half of 2025. Given the typical time lag between order receipt and
revenue recognition, we expect an uplift in revenue in H2 2025.  Demand for
GenIP's Generative AI analytics services is strong, and the Company is
laser-focused on growing its order book while continuing to maintain a robust
balance sheet.

 

Melissa Cruz, CEO of GenIP, commented:

 

"We are extremely encouraged by the strong commercial traction we've achieved
in such a short period since our IPO. The size and quality of our order book
reflect the value our services bring to clients worldwide. We're seeing
increasing demand for our solutions as institutions seek faster, data-driven
ways to unlock the value of their innovations. With a strong balance sheet and
a growing pipeline of opportunities, we are well positioned to deliver
accelerated growth in the second half of the year and beyond."

 

 

 

For further information regarding GenIP, please visit www.genip.ai
(http://www.genip.ai/) , or contact:

 

 GenIP Plc                                                                 Via Redchurch Communications

 Melissa Cruz, CEO

 Beaumont Cornish Limited (Nominated Adviser)                              Tel:  +44 (0) 20 7628 3396

 Roland Cornish / Asia Szusciak / Andrew Price

 Novum Securities Limited (Broker)                                         Tel: +44 (0)20 7399 9425

 Jon Belliss                                                               JBelliss@novumsecurities.com

 Redchurch Communications (Financial PR)                                   genip@weareredchurch.com (mailto:genip@weareredchurch.com)

 John Casey

The information communicated within this announcement is deemed to constitute
inside information as stipulated under the Market Abuse Regulations (EU) No
596/2014 which is part of UK law by virtue of the European Union (Withdrawal)
Act 2018.

 

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated
Adviser and is authorised and regulated by the FCA. Beaumont Cornish's
responsibilities as the Company's Nominated Adviser, including a
responsibility to advise and guide the Company on its responsibilities under
the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed
solely to the London Stock Exchange. Beaumont Cornish is not acting for and
will not be responsible to any other persons for providing protections
afforded to customers of Beaumont Cornish nor for advising them in relation to
the proposed arrangements described in this announcement or any matter
referred to in it.

 

Notes to Editors

 

About GenIP

 

GenIP provides generative artificial intelligence (GenAI) analytic services to
help companies, research institutions and venture funds assess and
commercialise new discoveries. GenIP combines expert human technical review
with GenAI algorithms to provide insightful and verified services.

 

GenIP provides two complementary services:

1.   Invention Evaluator: Provides bespoke research reports that assess the
market potential of new technological innovations and discoveries using
AI-driven proprietary software; and

 

2.   Vortechs: which is an executive recruitment service that uses
 advanced machine learning algorithms and natural language processing
technologies to assist in matching technology organisations with experienced
executives skilled in technology commercialisation.

 

The Company believes that its integrated GenAI service offerings will help
organisations to evaluate and commercialise their technological innovations.

Company Strategy

GenIP's goal is to be a leading Generative AI analytic services company. To
achieve this, the Company has established three strategic pillars:

 

●    Organically grow Invention Evaluator and Vortechs' revenue through
institutional and corporate connections as well as increase client pipeline
through marketing, advertising and social media spend.

●    Expand the Generative AI service offerings within Invention
Evaluator and Vortechs' to reach new customers and improve margins.

●    Bolt-on acquisitions of additional Generative AI services that are
helpful to our clients and have demonstrated initial market traction.

 

 

Forward looking statements

 

Certain statements contained in this announcement constitute forward-looking
statements. When used in this announcement, the words "may", "would", "could",
"will", "intend", "plan", "anticipate", "believe", "seek", "propose",
"estimate", "expect", and similar expressions, as they relate to the Company,
are intended to identify forward-looking statements. These statements include,
but are not limited to, statements regarding intentions, beliefs or current
expectations concerning, among other things, the Company's results of
operations, financial position, liquidity, prospects, growth, strategies and
expectations of the industry in which the Company operates.

 

Such statements reflect the Company's current views with respect to future
events and are subject to certain risks, uncertainties and assumptions. Many
factors could cause the Company's actual results, performance or achievements
to materially differ from those described in this announcement Should one or
more of these risks or uncertainties materialise, or should assumptions
underlying forward-looking statements prove incorrect, actual results may
differ materially from those described in this announcement as "intended",
"planned", "anticipated", "believed", "proposed", "estimated" or "expected".

 

For the avoidance of doubt, the contents of the Company's website and any
hyperlinks accessible from the Company's website are not incorporated by
reference into, and do not form part of, this announcement and investors
should not rely on them.

-ENDS-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTBUGDRRDDDGUS